Thermo Fisher Scientific (TMO) Net Cash Flow (2009 - 2026)

Thermo Fisher Scientific has disclosed Net Cash Flow across 18 years of filings, most recently posting -$6.7 billion for Q1 2026.

• Quarterly Net Cash Flow fell 7202.13% year-over-year to -$6.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (up 5.82% YoY) and the FY2025 annual result came in at $5.6 billion, up 240.49% from the prior year.
• Net Cash Flow fell to -$6.7 billion in Q1 2026, from $7.9 billion in the prior quarter.
• Over five years, Net Cash Flow peaked at $7.9 billion in Q4 2025 and troughed at -$6.7 billion in Q1 2026.
• A 5-year average of -$73.1 million and a median of -$356.0 million in 2024 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2025 — Net Cash Flow surged 2311.8% — and 2026, when it sank 7202.13%.
• Tracing TMO's Net Cash Flow over 5 years: stood at $5.4 billion in 2022, then slumped by 64.15% to $1.9 billion in 2023, then sank by 118.55% to -$356.0 million in 2024, then jumped by 2311.8% to $7.9 billion in 2025, then tumbled by 184.79% to -$6.7 billion in 2026.
• Business Quant data shows TMO's Net Cash Flow at -$6.7 billion in Q1 2026, $7.9 billion in Q4 2025, and -$2.5 billion in Q3 2025.